Bristol-Myers Squibb stock gains on positive Sotyktu data and solid Q2 figures
Published on 09/17/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock (ISIN US1078421011) is trading close to USD 63.60 on the New York Stock Exchange as of September 16, 2026, with investors focusing on fresh two-year data for the immunology drug Sotyktu in psoriatic arthritis and robust second-quarter 2026 results.
Sotyktu trial data provide a new catalyst
According to Bristol Myers Squibb on September 17, 2026, the Phase 3 POETYK PsA-2 study and its open-label extension showed durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis over two years of treatment.
The data are being presented at the Congress of Clinical Rheumatology - West, taking place from September 17 to September 20, 2026, highlighting Bristol-Myers Squibb's effort to expand Sotyktu beyond its existing indications in plaque psoriasis and psoriatic arthritis.
As MarketBeat notes on September 17, 2026, the most recent FDA-related event for Bristol-Myers Squibb was categorized as positive results, reflecting the company’s report of durable responses and a favorable safety profile for Sotyktu in psoriatic arthritis.
Q2 2026 results show revenue and EPS growth
For the fundamental backdrop, Bristol-Myers Squibb reported second-quarter 2026 revenues of USD 12,973 million, representing a 6 percent increase year over year from USD 12,233 million in the same quarter of 2025, according to Stock Titan citing the company’s Q2 2026 Form 10-Q.
In the same quarter, net earnings attributable to Bristol-Myers Squibb rose to USD 3,317 million, and GAAP diluted EPS increased to USD 1.62 from USD 0.64 a year earlier, while non-GAAP EPS climbed to USD 2.04 from USD 1.46, showing a substantial improvement in profitability driven by higher revenues and lower specified charges.
The Q2 2026 EPS of USD 2.04 beat the consensus estimate of USD 1.60 by USD 0.44, and revenue of USD 12.97 billion exceeded the consensus of USD 11.74 billion, according to an earnings overview cited by MarketBeat for Q2 2026.
Segment-wise, the Growth Portfolio generated Q2 2026 revenue of USD 7,560 million, a 15 percent increase year over year, while the Legacy Portfolio declined 4 percent to USD 5,422 million, illustrating a shift in the company’s revenue mix toward newer medicines, according to the same Stock Titan summary.
Within the Legacy Portfolio, Eliquis revenue in Q2 2026 reached USD 4,481 million, up 22 percent from the prior-year quarter, while generic erosion in Revlimid and Pomalyst continued to weigh on that segment, underscoring both the strength of Bristol-Myers Squibb’s cardiovascular franchise and the pressure on some oncology assets.
Dividend and analyst view support the shares
On the capital-return side, Bristol-Myers Squibb recently maintained its quarterly dividend, declaring a payout of USD 0.63 per share, payable on November 2, 2026, to shareholders of record on October 2, 2026, with the ex-dividend date also set for October 2, 2026, according to MarketBeat on September 16, 2026.
This quarterly dividend of USD 0.63 per share corresponds to an annualized dividend of USD 2.52, and BMY’s dividend yield stands around 3.95 percent with a payout ratio of 39 percent and a three-year dividend growth rate of 4.4 percent, suggesting a relatively sustainable income stream, as analyzed by GuruFocus on September 17, 2026.
Based on data compiled by MarketBeat, analysts currently rate Bristol-Myers Squibb stock as a Moderate Buy, with an average target price of approximately USD 66.72, implying upside of about 4.9 percent versus the recent closing level around USD 63.55 to USD 63.60.
An overview from MarketScreener on September 16, 2026, reports a similar analyst consensus, with an average target price of USD 66.71 and an ACCUMULATE opinion based on coverage from 28 analysts, reinforcing the view that the stock is expected to offer moderate appreciation potential.
That same MarketScreener data indicate that Bristol-Myers Squibb stock closed at USD 63.60 on September 16, 2026, which is about 4.9 percent below the average analyst target and up 17.91 percent year to date, while the five-day change was a modest negative 1.26 percent, suggesting the shares have already recovered significantly over 2026 but still trade below consensus valuation.
Valuation metrics from GuruFocus show a trailing twelve-month price-earnings ratio of 14.01 times for Bristol-Myers Squibb, below its five-year median P/E of 18.11 times, even though the stock is trading about 12.4 percent above the GF Value estimate of USD 56.60 at a current price around USD 63.60, highlighting a tension between historical valuation levels and one intrinsic-value model.
Key risks and pipeline dependence
For investors, one key risk is the ongoing generic competition facing Revlimid and Pomalyst, which has driven declines in the Legacy Portfolio and could continue to offset growth from newer products if erosion accelerates, as indicated in the Q2 2026 portfolio breakdown reported by Stock Titan.
Additionally, valuation analysis from GuruFocus suggests that Bristol-Myers Squibb stock is around 12.4 percent overvalued relative to its GF Value of USD 56.60, which could limit near-term upside if earnings growth or pipeline progress fails to outpace current expectations.
Ultimately, the durability and safety data for Sotyktu in psoriatic arthritis over two years, combined with strong Q2 2026 revenue and EPS growth and a 3.95 percent dividend yield, position Bristol-Myers Squibb stock as a pipeline-driven large-cap biopharmaceutical name where future performance will hinge on continued execution in immunology, oncology and cardiovascular franchises.
Stock price and market data
Per recent price data for the New York Stock Exchange, Bristol-Myers Squibb stock closed at about USD 63.55 to USD 63.60 on September 16, 2026, with a small daily decline of approximately 0.3 percent from the prior close and a five-day performance of minus 1.26 percent, while remaining roughly 4.9 percent below the analysts’ average target near USD 66.71 and up nearly 17.91 percent year to date.
Bristol-Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1078421011
- Ticker: BMY
- Trading venue: NYSE
- Price (as of September 16, 2026, 03:59): 63.55 USD
- Market capitalization: 129.80 billion USD (as of September 16, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 3, 2026
